Article
Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
17 Apr 2019
Abstract excerpt
BACKGROUND: Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment of children. This study evaluated recombinant human C1-INH (rhC1-INH) for HAE attacks in children. METHODS: This open-label, phase 2 study included children aged 2-13 years with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
